Neuroradiology · 2025
Dose-response and infusion duration of intra-arterial nimodipine in cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a single-center case series.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guenego Adrien, Salim Hamza Adel, Taccone Fabio Silvio, Heit Jeremy J, Wang Maud, Sadeghi Niloufar, Ligot Noémie, Lolli Valentina, Yedavalli Vivek, Wintermark Max, Tannouri Fadi, Lubicz Boris
Аннотация
BACKGROUND: This single-center case series evaluates the effects on arterial diameter, perfusion imaging, and safety of intra-arterial (IA) nimodipine administration for CV following aSAH.
METHODS: In this prospective single-center observational study (SAVEBRAIN PWI; NCT05276934), 14 patients with CV refractory to medical treatment were treated with IA nimodipine. We assessed changes in vessel diameter and perfusion parameters pre- and post-treatment. Associations between nimodipine dose, infusion duration, and outcomes were analyzed using regression models.
RESULTS: The median age of patients was 48 years; 50% were male. The median nimodipine dose was 2.00 mg with a median infusion duration of 10 minutes. Post-treatment, the median artery diameter increased from 1.50 mm to 1.90 mm (25% change), TMAX decreased from 2.58 to 2.11 seconds, and TTD decreased from 4.58 to 4.09 seconds. Higher nimodipine doses (> 2 mg) were associated with increased odds of hypotension requiring injection breaks (OR 3.6, 95% CI 2.1 to 5.6, p < 0.001). Retreatment was necessary in 69% of cases, with a median time to retreatment of 2 days.
CONCLUSIONS: IA nimodipine administration appears to improve vascular diameters and perfusion parameters in CV following aSAH but carries a significant risk of hypotension, especially at doses > 2 mg. Longer infusion durations may reduce hypotension risk. These findings emphasize the need for careful dose management and further research to standardize treatment protocols.
METHODS: In this prospective single-center observational study (SAVEBRAIN PWI; NCT05276934), 14 patients with CV refractory to medical treatment were treated with IA nimodipine. We assessed changes in vessel diameter and perfusion parameters pre- and post-treatment. Associations between nimodipine dose, infusion duration, and outcomes were analyzed using regression models.
RESULTS: The median age of patients was 48 years; 50% were male. The median nimodipine dose was 2.00 mg with a median infusion duration of 10 minutes. Post-treatment, the median artery diameter increased from 1.50 mm to 1.90 mm (25% change), TMAX decreased from 2.58 to 2.11 seconds, and TTD decreased from 4.58 to 4.09 seconds. Higher nimodipine doses (> 2 mg) were associated with increased odds of hypotension requiring injection breaks (OR 3.6, 95% CI 2.1 to 5.6, p < 0.001). Retreatment was necessary in 69% of cases, with a median time to retreatment of 2 days.
CONCLUSIONS: IA nimodipine administration appears to improve vascular diameters and perfusion parameters in CV following aSAH but carries a significant risk of hypotension, especially at doses > 2 mg. Longer infusion durations may reduce hypotension risk. These findings emphasize the need for careful dose management and further research to standardize treatment protocols.